参考文献:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. 美国食品药品监督管理局批准的药物标签用于研究药物诱导的肝损伤,《药物发现今日》,16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank:按发展药物诱导人类肝损伤风险排名的最大参考药物清单。《药物发现今日》2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
[EN] AN IMPROVED PROCESS FOR PREPARATION OF TRIENTINE DIHYDROCHLORIDE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE DICHLORHYDRATE DE TRIENTINE
申请人:EMCURE PHARMACEUTICALS LTD
公开号:WO2017046695A1
公开(公告)日:2017-03-23
The present invention provides a process for preparation of trientine dihydrochloride (1) comprising reaction of protected triethylene tetramine with hydrochloric acid in an aqueous system to yield the dihydrochloride salt wherein the formation of inorganic impurities and undesired salts is controlled significantly.
Composition, synthesis and therapeutic applications of polyamines
申请人:Murphy A Michael
公开号:US20050085555A1
公开(公告)日:2005-04-21
This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.
[EN] MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS<br/>[FR] DERIVES DE LA MITOQUINONE UTILISES EN TANT QU'ANTIOXYDANTS CIBLES DE MANIERE MITOCHONDRIALE
申请人:ANTIPODEAN BIOTECHNOLOGY LTD
公开号:WO2005019232A1
公开(公告)日:2005-03-03
This invention relates to pharmaceutically acceptable amphiphilic antioxidant compounds, compositions and dosage forms comprising said compounds, and methods and uses reliant on said compounds.The exemplified compounds are all mitoquinone derivatives, being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivatives. The compounds, compositions, dosage forms, uses and methods are useful in, for example, the treatment of diseases or conditions associated with oxidative stress.
COBALT-BASED MRI CONTRAST AGENT AND IMAGING SYSTEM
申请人:BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
公开号:US20160136305A1
公开(公告)日:2016-05-19
Novel, non-toxic cobalt-based contrast and imaging agents for use in enhanced medical imaging modalities and processes are described, as well the manufacture of markers containing such contrast agents is described, and uses for such imaging markers and contrast agents in a variety of therapeutic applications and devices.
[EN] A PROCESS FOR THE PREPARATION OF TRIENTINE DIHYDROCHLORIDE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DICHLORHYDRATE DE TRIENTINE
申请人:PIRAMAL ENTPR LTD
公开号:WO2019073427A1
公开(公告)日:2019-04-18
The present invention relates to an industrially feasible and economically viable process for preparation of trientine dihydrochloride of formula (I) in significantly high yield and purity.